Trial Profile
Aprepitant + paroxetine in combination treatment or individual monotherapy in patients with major depressive disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Nov 2015
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Paroxetine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co